1-2 of 2
Deborah Doss, RN, OCN
Close
Sort by
Journal Articles

A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or In Combination with Low-Dose Dexamethasone In Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib

Paul G Richardson, MD, David Siegel, MD, PhD, Rachid Baz, MD, Susan L. Kelley, MD, Nikhil C. Munshi, MD, Daniel Sullivan, MD, Melissa Alsina, MD, Deborah Doss, RN, OCN, Laura McBride, Gail Larkins, RN, Maria Lizza, BS, Xin Yu, Mohamed Zaki, MD, Christian J. Jacques, MD, Kenneth C. Anderson, MD
Journal: Blood
Blood (2010) 116 (21): 864.
https://doi.org/10.1182/blood.V116.21.864.864
Published: 2010
Journal Articles

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II Study

Paul Richardson, MD, Sagar Lonial, MD, Andrzej Jakubowiak, MD, PhD, Sundar Jagannath, MD, Noopur S Raje, MD, David Avigan, MD, Irene M Ghobrial, MD, Robert L Schlossman, MD, Amitabha Mazumder, MD, Nikhil C Munshi, MD, David H Vesole, MD, PhD, Robin Joyce, MD, Deborah Doss, RN, OCN, Diane L Warren, BS, Stephen W Hayes, Sarah Kaster, BS, Carol Delaney, BSN, Marisa Lauria, BA, Constantine Mitsiades, MD, PhD, Teru Hideshima, MD, PhD, Robert D. Knight, MD, Dixie-Lee Esseltine, MD, Kenneth C Anderson, MD
Journal: Blood
Blood (2008) 112 (11): 92.
https://doi.org/10.1182/blood.V112.11.92.92
Published: 2008